Cyanotis vaga

Cyanotis vaga: A Comprehensive Reference

1. Identity and Botanical Classification

Taxonomic Identity

Cyanotis vaga (Lour.) Schult. & Schult.f. is classified within the family Commelinaceae, subfamily Commelinoideae, tribe Tradescantieae, subtribe Cyanotinae, genus Cyanotis. The species name was formally published by J.J. Roemer and J.A. Schultes in Systema Vegetabilium, edition 15 bis, volume 7, page 1153 (1830), having originally been described by João de Loureiro as Tradescantia vaga in his Flora Cochinchinensis of 1790.

Synonyms and Related Names

Accepted synonyms include Tonningia vaga (Lour.) Kuntze (1891) and Cyanotis barbata D.Don, first described in the Prodromus Florae Nepalensis of 1825. Additional historical synonyms include Tradescantia barbata (D.Don) Spreng. (1827) and Tradescantia radicans Royle (1840). Further synonyms in the literature include Commelina hirsuta Hochst. (1841, nom. nud.), Cyanotis hirsuta Fisch., C.A.Mey. & Avé-Lall. (1842), and Cyanotis abyssinica A.Rich. (1850).

Geographic Distribution

Cyanotis vaga has a wide natural distribution encompassing tropical Africa, Yemen, the Himalayas, southern China, Indochina, and Java. The genus Cyanotis as a whole is native to Africa, southern Asia, and northern Australia, and comprises mainly perennial plants.

Botanical Description and Plant Family

Cyanotis vaga is a plant species belonging to the Commelinaceae family, commonly known as the spiderwort family. This plant is native to various regions, including parts of Asia and Africa, and is renowned for its rich content of ecdysteroids.

Relationship to Cyanotis arachnoidea

Cyanotis vaga is a related species to Cyanotis arachnoidea, a plant native to China that ranks among the richest known plant sources of phytoecdysteroids. While both species share chemical similarity, no Cyanotis species are recorded in the Chinese Pharmacopoeia; the ecdysteroid-containing plants officially recognized there are Cyathula officinalis (Chuan Niuxi) and Achyranthes bidentata (Huai Niuxi).

Common Forms and Preparations

In the modern market, Cyanotis vaga extract is commonly available in powdered form, often standardized to contain 1–20% ecdysteroids depending on the intended application. The extract may also be supplied as a capsule-ready powder for dietary supplements or as a research-grade material for preclinical studies, with standardization ensuring consistent potency for use in sports nutrition, functional foods, and nutraceutical products.

2. Traditional and Historical Use

Cultural and Geographic Traditions

Cyanotis vaga is a plant species belonging to the Commelinaceae family, traditionally used in various herbal and folk medicine practices in Asia and Africa. A member of the Commelinaceae family, it has long held a place in traditional medicine across various Asian cultures, particularly in India and China, where the aerial parts and roots were employed for their restorative and tonic properties. Traditional healers valued the plant for its perceived capacity to invigorate the body, enhance stamina, and support general well-being.

The extract derived from Cyanotis vaga has been traditionally used in Ayurvedic and Chinese medicine for its purported medicinal properties, which were attributed to bioactive compounds such as ecdysteroids and phytoecdysteroids.

Cyanotis vaga, found in parts of Asia and Africa, has been used in traditional systems of medicine, particularly in Ayurveda and certain folk medicine traditions, for supporting male reproductive health. In these contexts, extracts from the plant are reported to function as a general tonic, included in formulations intended to enhance vitality and male sexual function. Traditional uses are largely anecdotal and are often based on the plant's inclusion alongside other herbs in multi-ingredient preparations.

Nature and Limitations of the Historical Record

In Ayurvedic practices, Cyanotis vaga was reportedly used as a remedy for fatigue, weakness, and age-related debility, sometimes incorporated into rejuvenative tonics. Historically, extracts from Cyanotis vaga were utilized for their purported adaptogenic and wellness-promoting properties, with anecdotal accounts suggesting benefits in vitality and general health. It is important to note that these claims are based primarily on ethnobotanical reports and historical anecdote rather than documented systematic research. Scientific evidence for the efficacy of Cyanotis vaga in traditional therapeutic applications remains limited.

3. Key Constituents and Active Compounds

Phytoecdysteroids: Primary Active Class

Ecdysteroids are a class of naturally occurring compounds that are structurally similar to the insect molting hormone, ecdysone. Cyanotis vaga extract is a concentrated form of the plant's bioactive compounds, with ecdysterone being one of the most abundant and studied ecdysteroids present.

20-Hydroxyecdysone (ecdysterone or 20E) is a naturally occurring ecdysteroid hormone which controls the ecdysis (moulting) and metamorphosis of arthropods, and is one of the most common moulting hormones in insects and crustaceans. It is a phytoecdysteroid produced by and extracted from various plants, including Cyanotis vaga, Ajuga turkestanica, and Rhaponticum carthamoides, and is thought to serve as a plant defense against herbivory by disrupting the reproduction of insect pests.

The molecular formula of ecdysterone is C₂₇H₄₄O₇ (2β,3β,14α,20β,22R,25-hexahydroxy-5β-cholest-7-en-6-one), and it is an ingredient added to some commercial products, including dietary supplements with claims of ability to enhance physical performance.

Chemical Complexity and Ecdysteroid Profile

The structural complexity of 20-hydroxyecdysone, bearing six hydroxyl groups, presents fundamental challenges for selective chemical modification; furthermore, the pronounced hydrophilicity of the polyol framework paradoxically results in poor aqueous solubility at physiologically relevant concentrations, limiting bioavailability of the parent compound.

Phytoecdysteroids like 20-hydroxyecdysone ("ecdysterone") can exert a mild, non-hormonal anabolic/adaptogenic activity in mammals, and as such are frequently used in food supplements. The extract also contains other phytochemicals, and it has been described as rich in antioxidants and amino acids, contributing to its potential therapeutic properties.

4. Mechanisms of Action

Arthropod vs. Mammalian Receptors

In arthropods, 20-hydroxyecdysone acts through the ecdysone receptor; although mammals (including humans) lack this receptor, 20-hydroxyecdysone affects mammalian biological systems.

Estrogen Receptor Beta (ERβ) Involvement

Studies have elucidated the mechanism of action of 20-hydroxyecdysone on human muscle cells, which appears to involve relatively selective activation of estrogen receptor beta (ERβ), known to result in muscle hypertrophy.

In vitro experiments demonstrated that 20E-induced hypertrophy and protein synthesis were prevented by a GPCR inhibitor in differentiating C2C12 myoblasts. The hypertrophying effect of 20E on these cells was similar to that of the beta-oestrogen receptor agonist and was prevented by a beta-oestrogen receptor-selective antagonist. However, no direct binding of 20E has been demonstrated to the beta-oestrogen receptor, and involvement of a membrane-bound receptor was supported by the effectiveness of protein-bound 20E.

Despite more than 40 years of research, the mechanism of action of these molecules in mammals and humans has not been fully elucidated, with only diverging reports available. Several data favour an action on membranes through a GPCR receptor, whereas others suggest the involvement of the nuclear receptor ERβ. There is in fact no direct evidence for the binding of 20E to nuclear estrogen or androgen receptors.

PI3K/Akt/mTOR Pathway and Protein Synthesis

To study the mechanism of action of phytoecdysteroids in mammalian tissue, an in vitro cellular assay of protein synthesis was developed. In C2C12 murine myotubes and human primary myotubes, phytoecdysteroids increased protein synthesis by up to 20%. In vivo, ecdysteroids increased rat grip strength. Ecdysteroid-containing plant extracts produced similar results, and the effect was inhibited by a phosphoinositide kinase-3 (PI3K) inhibitor, suggesting a PI3K-mediated mechanism.

MAS Receptor and the Renin–Angiotensin System

MAS receptor, as the protective arm of the renin–angiotensin system (RAS), has been proposed as a feasible interpretation for the pleiotropic effects of 20E, with a cooperative activity between MAS and a palmitoylated (membrane-bound) estrogenic receptor proposed for the mechanism of 20E action in the renin–angiotensin–aldosterone system.

Interestingly, angiotensin 1–7, the endogenous ligand of the MAS receptor, had a similar hypertrophic effect on C2C12 myogenic cells as 20E, and the endogenous muscle growth inhibitor myostatin was partially suppressed by both 20E and angiotensin 1–7.

NF-κB and Cardiovascular Pathways

It has been shown that 20E exerts its effect through SIRT6-mediated deacetylation of NF-κB p65 to inhibit CD40 expression in 3-D human endothelial cell (HUVEC) culture, with the authors proposing that 20E may have therapeutic potential for the treatment of cardiovascular diseases.

5. Scientific Evidence by Area of Use

5.1 Skeletal Muscle Hypertrophy and Athletic Performance

In Vitro and Animal Evidence

In C2C12 murine myotubes and human primary myotubes, phytoecdysteroids increased protein synthesis by up to 20%, and in vivo, ecdysteroids increased rat grip strength. Dose–response analysis showed that the protein synthesis stimulatory activity of 20E in C2C12 myotubes is equally potent as insulin-like growth factor-1 (IGF-1). Myotube growth is mediated negatively by myostatin, and 20E mimics the effect of IGF-1 in reducing myostatin gene expression in a dose-dependent manner, with significant differences from the control occurring at 1–10 μM.

Key Human/Clinical Evidence

The most cited human study examining ecdysterone as the key constituent of Cyanotis vaga-type supplements is the 2019 publication by Isenmann et al. in Archives of Toxicology. This study showed that 10-week supplementation of ecdysterone at 12 mg daily and 48 mg daily in young men contributed to the improvement of anthropometric and performance parameters, with significantly higher increases in muscle mass observed in participants dosed with ecdysterone. Significantly higher increases in muscle mass were observed in dosed participants. The same hypertrophic effects were also detected in vitro in C2C12 myotubes.

Isenmann et al. conducted a 10-week randomized controlled trial involving strength training for young men (n=46). Notably, participants supplemented with the high-dose ecdysterone preparation (48 mg of ecdysterone) showed a significant increase in muscle mass (2.0 kg delta).

The Isenmann et al. study also revealed a significant labeling discrepancy: the actual amount of ecdysterone in the capsules used was only 6 mg, whereas the declared amount was 100 mg. This indicated falsification in the declared ecdysterone dose and the presence of counterfeits among some dietary supplements.

A second, earlier human trial by Wilborn et al. (2006) examined outcomes in a larger cohort: forty-five resistance-trained males (average age 20.5 years) were randomly assigned in a double-blind manner to receive either placebo, 800 mg/day of methoxyisoflavone, 200 mg/day of 20-hydroxyecdysone, or 1,000 mg/day of sulfo-polysaccharide for 8 weeks during training. At 0, 4, and 8 weeks, participants underwent assessments for muscular strength, muscular endurance, anaerobic capacity, and body composition. This 2006 study concluded that the use of 30 mg per day of 20-hydroxyecdysone administered orally did not significantly affect anabolic or catabolic responses to resistance training, body composition, or training adaptations.

A more recent 2025 study published in the Journal of the International Society of Sports Nutrition further explored phytosteroid combinations: phytosteroids like 20-hydroxyecdysone (20E) and diosgenin (DSG) have shown promising anabolic and performance-enhancing effects in in vitro, animal, and human studies. Combining phytosteroids is common in supplements, with early in vitro research suggesting additive effects via distinct signaling pathways; however, human studies on the combined effects of 20E and DSG were lacking. Twenty-eight resistance-trained young men were recruited and randomized into a 20E-and-DSG group or a placebo group.

An additional human study examined ecdysterone in the context of sarcopenia in older adults: the SARA-INT trial investigated whether BIO101 (20-hydroxyecdysone), described as an activator of the MAS receptor, is safe and improves muscle function and physical performance in community-dwelling older sarcopenic patients. It was a randomized three-arm interventional study (BIO101 175 mg twice daily / 350 mg twice daily / placebo) with planned 6-month treatment, enrolling men and women aged ≥65 years meeting FNIH sarcopenia criteria and SPPB score ≤8/12.

Evidence strength summary: The human/clinical evidence base for the anabolic and performance-enhancing effects of 20-hydroxyecdysone (the principal active in Cyanotis vaga supplements) is preliminary and mixed. The number of completed randomized controlled trials in humans is small, sample sizes are modest, and study durations range from 8 to 10 weeks. Results conflict across trials. The most positive findings (Isenmann et al., 2019) were confounded by supplement mislabeling. Robust, independently replicated, large-scale RCTs are not yet available.

5.2 Metabolic Health: Blood Glucose, Lipids, and Obesity

In animal studies, 20E revealed anabolic, antioxidant, antidiabetic, anti-obesity, cardioprotective, neuroprotective, hepatoprotective, and other biological effects.

The daily oral administration of 20E decreased body weight, hyperglycaemia, and plasma insulin level, and ameliorated insulin resistance and obesity in high-fat-fed control mice. The effect of 20E was also studied in the streptozotocin-induced type I diabetic rat model; after 30 days of oral administration, plasma levels of glucose, glycated haemoglobin (HbA1C), and insulin were lowered, and the levels of glucose uptake enzyme (hexokinase) and glucose-6-phosphate dehydrogenase were increased, whereas gluconeogenic enzymes were decreased.

Oral administration of 5 mg 20E/kg body weight per day to STZ-induced diabetic rats for 30 days reduced fasting blood levels of glucose, cholesterol, free fatty acids, glycerol, phospholipids, LDL, and VLDL, and elevated HDL, lipoprotein lipase, and lecithin cholesterol acyl transferase in plasma compared with diabetic control rats. This effect was likened to that of the antidiabetic drug glibenclamide.

In a rat model of cardiometabolic syndrome induced by high-fat high-fructose diet combined with ovariectomy, some characteristics of the syndrome were improved by 20E treatment. Treated rats had lower body weight and abdominal fat accumulation compared with vehicle-treated controls, without changes in total caloric intake or fat-free mass. Rats receiving 20E maintained normal blood pressure and had lower LDL-cholesterol levels. Although 20E showed no positive effect on inducing insulin-mediated glucose transport in skeletal muscle, it improved whole-body glucose homeostasis, and analysis of liver protein expression revealed significantly increased expression of pAkt, pFOXO1, pAMPKα, and FGF21.

20-hydroxyecdysone (20E) is described in recent literature as a 'green anabolic' dietary supplement with beneficial effects in some animal models of metabolic disease. In a high-fat high-sugar diet (HFHSD)-induced obesity rat model, both 20E and its derivative calonysterone (CAL) normalized changed plasma concentrations of adiponectin and leptin after the high-calorie diet.

Evidence strength: All metabolic evidence cited above derives from in vitro cell experiments and animal (rodent) models. No published randomized controlled clinical trial has specifically and rigorously investigated the metabolic effects of Cyanotis vaga extract or isolated 20E in human subjects with diabetes, obesity, or dyslipidemia as primary endpoints.

5.3 Antioxidant Effects

20E displays anabolic, hypolipidemic, anti-diabetic, anti-inflammatory, hepato- and cardioprotective, antioxidant, antihypertensive, anti-fibrotic, and anti-COVID properties, among others. It is an arthropod hormone which is synthesized by some plants as part of their defense mechanism; in humans, 20E has no hormonal activity but possesses a number of beneficial pharmacological properties. Recent studies have shown that 20E may also possess antineoplastic activity.

In non-small cell lung cancer (NSCLC) cell lines, 20E displayed significant antioxidant capacities and induced expression of antioxidative stress response genes. RNA-seq analysis of 20E-treated lung cancer cells revealed the attenuation of genes involved in different metabolic processes, including the suppression of several enzymes of glycolysis and one-carbon metabolism, as well as their key transcriptional regulators c-Myc and ATF4.

Evidence strength: Antioxidant effects of 20E are demonstrated primarily in cell-culture and animal models. Clinical evidence in humans is absent.

5.4 Neuroprotective, Cardioprotective, and Hepatoprotective Effects

20E possesses pharmacological properties described as including adaptogenic, hypoglycemic, and antioxidant properties, as well as cardio-, hepato-, and neuroprotective features in preclinical settings. A recent study found that 20E exerts its effect through SIRT6-mediated deacetylation of NF-κB p65 to inhibit CD40 expression in 3-D human endothelial cell culture (HUVEC), leading researchers to propose that 20E may have therapeutic potential for the treatment of cardiovascular diseases.

Evidence strength: These effects are preclinical (in vitro and animal studies) and have not been validated in controlled human clinical trials for any of these specific organ systems.

5.5 Anti-Parasitic and Antimicrobial Properties

Anti-parasitic activity of 20-hydroxyecdysone against human filarial parasites has been described in the scientific literature. Ecdysteroids are widely used by athletes as dietary supplements to increase strength and muscle mass during resistance training, to reduce fatigue and to ease recovery. Clinical evidence in this area remains absent; a registered clinical trial (NCT04827537) was designed to assess anti-protozoal activity of 20-hydroxyecdysone in water sports athletes with giardiasis, but results from this trial are not yet reported in the published literature.

6. Body Systems Associated with Cyanotis vaga

• Musculoskeletal system: Skeletal muscle hypertrophy, protein synthesis, anti-atrophic effects (studied in vitro and in some RCTs).
• Endocrine/metabolic system: Glucose homeostasis, insulin sensitivity, lipid metabolism, anti-obesity effects (animal models).
• Cardiovascular system: Blood pressure, lipid profiles, endothelial function (preclinical evidence).
• Nervous system: Neuroprotective effects (preclinical only).
• Hepatic system: Hepatoprotective properties (preclinical).
• Immune/antioxidant system: Modulation of oxidative stress, NF-κB signaling (preclinical).
• Reproductive system: Traditional use as a tonic for vitality, with no established clinical evidence.

7. Dosage Forms and Dosages Reported in Studies

The most thoroughly conducted study, performed by Isenmann et al., used ecdysterone at 12 mg daily and 48 mg daily in young men over 10 weeks. The Wilborn et al. (2006) study administered 200 mg/day of 20-hydroxyecdysone to resistance-trained males over 8 weeks. The SARA-INT trial examined BIO101 (20-hydroxyecdysone) at doses of 175 mg twice daily and 350 mg twice daily over up to 9 months in sarcopenic adults aged ≥65 years.

Animal model studies have employed oral doses of 5 mg 20E/kg body weight per day administered to diabetic rats over 30 days. Other animal studies have used intragastric administration of 20E at 5 mg/kg, 10 mg/kg, or 20 mg/kg body weight for 8 weeks.

In the commercial supplement market, Cyanotis vaga extract is commonly standardized to contain 1–20% ecdysteroids, depending on the intended application. 20E displays low toxicity, with an LD₅₀ in mice reported to be 9 g/kg of body weight.

8. Safety Considerations

Clinical Safety Profile

In short-term human clinical trials, ecdysterone has demonstrated a favorable safety profile compared to prohibited anabolic agents. A 10-week study in young men found that daily supplementation did not result in significant increases in biomarkers for liver or kidney toxicity. Participants did not report typical hormonal side effects, such as changes in libido or mood, often seen with traditional steroids.

The most frequently reported adverse effect is mild gastrointestinal distress, including nausea or an upset stomach. This reaction is usually transient and dose-dependent, often resolving as the body adjusts to the supplement.

The long-term safety of ecdysteroid supplementation remains undetermined due to the limited duration of current human studies. A significant concern arises from mechanistic animal research suggesting potential kidney damage over time.

Hormonal Non-Interference

In arthropods, 20-hydroxyecdysone acts through the ecdysone receptor. Mammals (including humans) lack this receptor, meaning 20-hydroxyecdysone cannot interact with the mammalian ecdysone receptor. Experimental studies indicate that ecdysterone enhances protein synthesis and physical performance through estrogen receptor-beta activation, avoiding the adverse effects typically associated with anabolic-androgenic steroids.

Regulatory Status and WADA Monitoring

The World Anti-Doping Agency (WADA) added ecdysterone to its Monitoring List in 2020 due to its demonstrated anabolic potency. This action signifies that the substance is being closely tracked to determine if it should be moved to the Prohibited List.

Researchers involved in the pivotal Isenmann et al. study suggested that ecdysterone should be included on the WADA Prohibited List as "other anabolic agent."

In terms of food law, Cyanotis vaga, together with Achyranthes aspera, Cyathula capitata, Pfaffia paniculata, and Polypodium virginianum, is banned by Hungary's National Institute for Food and Nutrition Science (OÉTI) and, as such, cannot be marketed as a food supplement in Hungary.

Product Quality and Mislabeling Risks

Independent testing frequently reveals that the actual amount of ecdysterone in commercial products is far lower than the quantity declared on the label, or that the product is contaminated. This lack of purity and standardization means consumers may not be taking the intended substance or dose, introducing unpredictable safety risks. Contamination with undisclosed and prohibited substances, including actual anabolic steroids, is a serious concern for athletes.

Ecdysteroids are generally considered non-toxic in humans; however, analysis of commercial supplements frequently reveals poor quality control.

Metabolism and Excretion

Few studies are available in the recent literature on the metabolism of ecdysterone. The breakdown of ecdysterone differs considerably between species, generating different metabolites. For example, in human urine, deoxy-ecdysterone metabolites are reported as 2-deoxyecdysterone, deoxyecdysone, and 14-deoxy-ecdysterone. The inclusion of ecdysteroids on WADA's monitoring list has regenerated interest in investigating the metabolism and prevalence of use in humans.

9. Overall Evidence Assessment

Scientific investigations into Cyanotis vaga are still in their early stages, but several preliminary studies have explored its pharmacological potential. While many effects have been described in animal studies, the clinical evidence for 20E effectiveness in humans remains limited. The body of evidence supporting the use of Cyanotis vaga extracts as a dietary supplement is therefore characterized by the following:

• A rich in vitro and animal literature documenting multiple biological mechanisms including PI3K/Akt/mTOR signaling, estrogen receptor beta activation, myostatin suppression, and NF-κB modulation.
• A small number of human RCTs, with conflicting results on anabolic and performance outcomes, modest sample sizes, and short durations.
• No published human RCTs investigating metabolic, cardioprotective, hepatoprotective, or neuroprotective clinical endpoints.
• A documented problem of product mislabeling and adulteration in commercial preparations containing ecdysteroids from the Cyanotis genus.
• An unresolved mechanistic debate—despite decades of research, no single primary molecular target for 20E in mammals has been definitively confirmed.

References

• Plants of the World Online – Cyanotis vaga (Lour.) Schult. & Schult.f. (Royal Botanic Gardens, Kew)
• World Flora Online – Cyanotis vaga (Lour.) Schult.f.
• Wikispecies – Cyanotis vaga (taxonomy and synonymy)
• Wikipedia – Cyanotis (genus overview and species distribution)
• Wikipedia – 20-Hydroxyecdysone (pharmacology, clinical studies, WADA status)
• Dávid Boros et al. (2016). Ecdysteroid-containing food supplements from Cyanotis arachnoidea on the European market: evidence for spinach product counterfeiting. Scientific Reports. PMC5144001.
• Isenmann E, Ambrosio G, Joseph JF, et al. (2019). Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. Archives of Toxicology, 93(7), 1807–1816.
• Gorelick-Feldman J, MacLean D, Ilic N, Poulev A, et al. (2008). Phytoecdysteroids increase protein synthesis in skeletal muscle cells. Journal of Agricultural and Food Chemistry, 56(10), 3532–3537.
• Parr MK et al. (2014). Estrogen receptor beta is involved in skeletal muscle hypertrophy induced by the phytoecdysteroid ecdysterone. Molecular Nutrition & Food Research.
• Zádor E et al. (2025). Molecular Targets of 20-Hydroxyecdysone in Mammals, Mechanism of Action: Is It a Calorie Restriction Mimetic and Anti-Aging Compound? Cells, 14(6), 431.
• Sarachana Tanummee et al. (2020). 20-Hydroxyecdysone ameliorates metabolic and cardiovascular dysfunction in high-fat-high-fructose-fed ovariectomized rats. BMC Complementary Medicine and Therapies. PMC7203795.
• Barbalat V et al. (2023). 20-Hydroxyecdysone Confers Antioxidant and Antineoplastic Properties in Human Non-Small Cell Lung Cancer Cells. PMC10223942.
• Lafont R et al. (2021). 20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases. Biomedicines. PMC8146789.
• Analytical strategy for the detection of ecdysterone and its metabolites in vivo. PMC9291035.
• SARA-INT Trial: BIO101 in Sarcopenic Seniors at Risk of Mobility Disability. PMC11873539.
• Investigation of calonysterone and 20-hydroxyecdysone effects in high-fat, high-sugar diet-induced obesity rat model. PMC11847253.
• Ecdysterone: A Component of Dietary Supplements with Ergogenic Potential? Sports (MDPI), 6(2), 31.
• How reliable is the labeling of a commercial phytosteroid product? A 12-week randomized double-blind training study. Journal of the International Society of Sports Nutrition (2025).
• Ergogenic properties, safety evaluation and regulations of selected ingredients in testosterone booster dietary supplements. Critical Reviews in Food Science and Nutrition (2023).
• Ecdysteroids: production in plant in vitro cultures. PMC5559567.
• ClinicalTrials.gov – NCT04827537: Anti-Protozoal Effect of Steroid Hormone 20-Hydroxyecdysone.
• β-Cyclodextrin Inclusion Complexes of 20-Hydroxyecdysone Derivatives: Synthesis, NMR Characterization, and In Vitro/In Vivo Evaluation. Pharmaceuticals (2026).